Yep, first shot on goal was a flop. Can't see clinical or commercial success for HER2.
Prostate is a possibility. But huge competition from existing and pipeline products. TLX, CU6, RAD are in the prostate cancer imaging space. Sure, MRI easier than PET, if it works that is.
This company will take YEARS to even start trials in prostate or others.
Ann: Imagion Announces Positive Results from Phase 1 Study, page-25
Add IBX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
6.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $2.219M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 6486 | 6.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.8¢ | 2407 | 2 |
View Market Depth
| Last trade - 11.13am 17/07/2024 (20 minute delay) ? |
| IBX (ASX) Chart |
Day chart unavailable